COMMUNIQUÉS West-GlobeNewswire

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
26/03/2026
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
26/03/2026
Reported positive results from potentially registrational Phase 2 trial of LB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation of a pivotal Phase 3 NOVA-2 trial in [...]
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 [...]
Galapagos Announces Nomination of Gino Santini to its Board of Directors
26/03/2026
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership [...]
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
26/03/2026
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25 Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to [...]
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT [...]
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026
26/03/2026
Conférence téléphonique et diffusion en direct sur Internet le mercredi 1er avril 2026 à 14h00 CEST / 8h00 EDT PARIS et CAMBRIDGE, Mass., 26 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – [...]
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/03/2026
CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
26/03/2026
New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical [...]
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
26/03/2026
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
SIGA Declares Special Cash Dividend of $0.60 Per Share
26/03/2026
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0. [...]
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 [...]
Premier Health Announces Results of Shareholders’ Meeting
26/03/2026
MONTRÉAL, March 26, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Company ” or “ Premier Health ”), a leading Canadian Healthtech company, announces that all matters submitted to [...]
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings
26/03/2026
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ [...]
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
26/03/2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ [...]
Precision Optics Corporation, Inc. Announces Proposed Public Offering of Common Stock
26/03/2026
GARDNER, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries [...]
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
26/03/2026
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phase 3, randomized, [...]
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March [...]
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for [...]

Pages